If GST will not be with us for too long, it makes no sense to hold preferred B at the current price. It could get called (at $25) before one can recoup the $1 premium. Preferred A is a different story.
GNBT's finance does not bother me at this time. If the phase ll result ( which they said show benefit for the node negative patients ) is statistically significant, the company will be in a position to raise fund or sell out at a premium or sign up with a strong partner. May be GALE's partners ? I will let go of GALE if that happens. However there is no guarantee if either or both AE37 or E75 will be statistically significant in phase lll - so I keep some exposure to GALE.
Bashers or negative articles do not bother me. These garbage articles reside in the day-weeek-trader worlds.
I thought about that too. I wonder why GALE has not already make a move. GNBT 's result is actually very positive for GALE. In the end science is all that matters for both GALE and GNBT so I am actually very surprised GALE got hit like this today. Well, I will keep both.
It is "you are" or "you're", not "your".
The science speaks for itself and both GALE and GNBT data agree.
AE37 works on CD4+ T cells whereas E75 on CD8+T cells. Chances are AE37 will work better but of course it all depends on the patient population each testing so the jury is still out there. That is why I am keeping half of GALE position but increase my GNBT position.
I spent more than 100X of your alleged $40 today on GNBT, that is peanut to me.
I don't think GALE sank on this much discussed article. Take a look at the press release of GNBT today. Good news, they are to release their result in May and the submitted abstracts available then. However, they did say this " While full analysis of the recent results is still in progress, the data corroborate qualitatively the data reported after an interim analysis conducted two years ago. Specifically, the more prevalent population of breast cancer patients ineligible to receive the drug Herceptin, and particularly those in high-risk groups (e.g., triple negative breast cancer), appear to benefit most from AE37. "
Good because it implies GALE's result is valid. Bad because AE37 , I think, may work better than GALE's. I dumped half of my GALE this morning and moved money over to GNBT.
GALE is now down 114% while GNBT up almost 11%.
Frontier Capital Management subscribes to the same Financial News letter as the Fidlelity management, so did Eagle Asset Management but not American Funds. Ridiculous questions deserve silly answers.
Why ? Don't you know ? The managers of these Fidelitiy funds all subscribe to the same financial news letter which has a sell rating on IOC.
Same here exceptfor EMES , GNBT and SDS.
So far GNBT has gone up 18% today.
$10.5 billion is nothing for a pharmaceutical company. Most big pharms have only 2 - 4 real money making drugs.